GW&K Investment Management LLC Acquires 323,674 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

GW&K Investment Management LLC grew its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,123,488 shares of the medical device company's stock after acquiring an additional 323,674 shares during the period. GW&K Investment Management LLC owned 3.23% of Tandem Diabetes Care worth $76,488,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in TNDM. Baillie Gifford & Co. increased its stake in shares of Tandem Diabetes Care by 235.7% during the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after purchasing an additional 523,843 shares during the period. Bellevue Group AG grew its holdings in Tandem Diabetes Care by 19.9% in the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock valued at $78,496,000 after buying an additional 307,624 shares in the last quarter. Stephens Investment Management Group LLC increased its position in Tandem Diabetes Care by 22.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock worth $56,040,000 after buying an additional 281,327 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Tandem Diabetes Care by 397.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company's stock worth $11,121,000 after buying an additional 240,966 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Tandem Diabetes Care in the third quarter valued at about $10,208,000.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms recently commented on TNDM. The Goldman Sachs Group lowered their price target on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $35.00 to $24.00 in a report on Tuesday. Wells Fargo & Company reiterated an "equal weight" rating and issued a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a research note on Monday. Canaccord Genuity Group reissued a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Finally, Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the company from $35.00 to $25.00 in a research report on Friday. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $46.81.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock traded down $1.29 during mid-day trading on Tuesday, reaching $19.49. The company had a trading volume of 4,141,847 shares, compared to its average volume of 1,462,378. The business has a fifty day simple moving average of $34.63 and a 200 day simple moving average of $36.16. The company has a market cap of $1.30 billion, a P/E ratio of -10.10 and a beta of 1.32. Tandem Diabetes Care, Inc. has a fifty-two week low of $18.77 and a fifty-two week high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.